Phyllodes Carcinoma of the Breast: An Uncommon Case Report

Benaouicha Nisrine 1*, Slaoui Aziz 1, Louzali FZ 1, Zeraidi Najia 1, Pr Lakhdar Amina 1, Aicha Kharbach 2, Baydada Aziz 1

1 Gynecology-Obstetrics and Endoscopy Department, Maternity Souissi/ University Hospital Center IBN SINA, Rabat Morocco
2 Gynecology-Obstetrics and Endocrinology Department, Maternity Souissi/ University Hospital Center IBN SINA, Rabat Morocco

DOI: 10.36348/siog.2022.v05i04.012 | Received: 16.03.2022 | Accepted: 21.04.2022 | Published: 29.04.2022

*Corresponding author: Benaouicha Nisrine
Gynecology-Obstetrics and Endoscopy Department, Maternity Souissi/ University Hospital Center IBN SINA, Rabat Morocco

Abstract

Cystosarcoma phyllodes of the breast are rare, and it accounts for less than 1% of the malignant tumors of the breast. Its clinical and radiological characteristics are those of benign tumors, and only a fast tumoral growth can evoke diagnosis. The diagnosis is confirmed by anatopathology and immunohistochemistry. Surgical extended resection is the treatment of choice. Adjuvant radiotherapy may be administered in patients with high-grade tumors, positive surgical margins, or postoperative recurrence. Here we present a case of a woman affected by a sarcoma phyllodes tumor, an uncommon oncologic disease.

Keywords: Sarcoma phyllodes, mastectomy, radiotherapy, immunohistochemistry.

Copyright © 2022 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

Phyllodes tumors have an incidence of 1 per 100,000 women and account for only 0.5% of all breast neoplasms [1]. They are classified into benign, malignant, and borderline tumor according to histopathological features [2]; its clinical course is frequently unpredictable. The malignant phyllodes tumor is rare with a lower incidence than the benign counterpart.

Phyllodes sarcomas of the breast have clinical and mammographic signs that are comparable to those of benign lesions; the anatopathological analysis of surgical parts requires a reference anatopathologist and immunohistochemistry for the confirmation [3]. Surgical resection remains the gold standard of treatment, whereas radiation therapy and chemotherapy have an undefined role.

In this case report, we discuss a patient who developed a rapidly expanding malignant phyllodes breast tumor. Through this work, we would like to focus on the the circumstances of the occurrence of these tumors, on the difficulties of clinical and paraclinical diagnosis as well as the therapy.

CASE PRESENTATION

We report a case of a 27-years-old female with no history of familiar breast tumor or ovarian cancer, G1P1 cesarean delivery for fetal distress. The patient consulted for a painless mass in the right breast that appeared suddenly and rapidly increased in size. The senological examination found a mass in the supero-external quadrant of the right breast, measuring 10 cm/9cm painless fixed, without cutaneous sign opposite or galactorrhea. No axillary lymph node was palpable. The examination of the left breast was normal (Fig1).
well circumscribed lobulated and heterogeneous contours, highly vascularized by Doppler, requiring a histological confrontation to eliminate a phyllodes tumor (Fig2): ACR4 on the right and 1 on the left. A microbiopsy with immunohistochemistry study was carried out showing a phyllodes sarcoma. An extension evaluation was done: no secondary localisation on thoraco-abdominal-pelvic CT scan.

The right breast and major pectoral muscle were excised (Fig3) with healthy surgical margins on anathomopathological examination. The postoperative course was normal and the patient benefited from adjuvant radiotherapy.

**DISCUSSION**

Phyllodes sarcoma of the breast is rare, less than 1% of all breast cancers breast [4]. It differs from primary breast sarcoma by the presence of both epithelial and connective elements at the same time. This is the definition of phyllodes tumors which are classified in three grades: grade I: benign; grade II: borderline and grade III: malignant. The predominance of the conjunctive element is a criterion of malignancy that defines grade III; it is the phyllodes sarcoma [5].
It occurs mainly in middle-aged women. As reported in literature, mean age ranges from 30 to 52 years [6]. The pathophysiology of these tumors remains unknown.

The difficulty in distinguishing between phyllodes carcinomas and benign fibroadenoma may lead to misdiagnosis. In fact, there are no characteristic features that clinically distinguish phyllodes carcinoma from other breast tumors.

The tumor is found in 30% of cases in the in the superior-external quadrant, its size can vary from a few centimeters to several tens of centimeters of long axis, between 1 and 21 cm for Confavreux et al. [7]; it is multilobulated and not fixed to the cutaneous or deep plane [7]. In our case, the tumor measures 10 cm; it is located on the right in the superior-external quadrant without associated lymph node involvement.

Lymph node involvement is uncommon for sarcomas, as they rarely metastasize to the lymph nodes [8], but it can occur and can reach 8% of cases [7].

The mammography and ultrasound do not make the diagnosis of phyllodes carcinoma; the diagnosis is mainly histological [9], by microbiopsy or macrobiopsy or on lumpectomy or mastectomy. Immunohistochemistry is currently an indispensable tool for the confirmation of the histological type [10]. In our case, the diagnosis was made by microbiopsy associated with immunohistochemical study.

Surgical treatment is generally the treatment of choice for phyllodes tumors, regardless of its histological subtype. Most studies recommend a more than 1- to 2-cm excision margin [10] based on the evidence that local recurrence occurs more frequently in patients with narrow surgical margins less than 1 to 2 cm. The study of the margins of the surgical specimen is therefore very important, especially in the case of partial conservative surgery. Our patient had a total mastectomy with excision of the pectoral muscle as the tumor was multifocal and infiltrating the muscle.

The postoperative radiotherapy increases the five-year survival rate and decrease the local recurrence rate [12]. Currently it is indicated in case of a safety margin less than 10 mm or in case of local recurrence. Several chemotherapy protocols have been used without providing any benefit in terms of survival.

Hormone therapy has not yet been studied for this type of pathology. About our patient, the evolution was favorable without local recurrence or metastasis.

After excision, the prognostic factors of phyllodes sarcoma correspond to the histological grade, surgical margins, and the presence of tumor necrosis. Tumor size would also be a pejorative factor [13].

**CONCLUSION**

Phyllode sarcoma is a separate entity of breast cancers, it is rare, and it is completely different from epithelial cancer. Its epidemiology is particular as well as it presents difficulties in clinical and paraclinical diagnosis. The treatment is based on surgery which can be a large lumpectomy or a mastectomy, lymph node dissection is unnecessary, and the prognosis depends on several factors, the most important of which is the margins of surgical resection.

**REFERENCES**

1. Moffat, C. J. C., Pinder, S. E., Dixon, A. R., Elston, C. W., Blamey, R. W., & Ellis, I. O. (1995). Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. *Histopathology*, 27(3), 205-218.
2. Eble, J. N., Tavassoli, F. A., & Devilee, P. (Eds.). (2003). *Pathology and genetics of tumours of the breast and female genital organs*. Iarc.
3. Stebbing, J. F., & Nash, A. (1995). Diagnosis and management of phyllodes tumour of the breast: experience of 33 cases at a specialist centre. *Annals of the Royal College of Surgeons of England*, 77(3), 181.
4. Guerrero, M. A., Ballard, B. R., & Grau, A. M. (2003). Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. *Surgical oncology*, 12(1), 27-37.
5. Confavreux, C., Lurkin, A., Mitton, N., Blondet, R., Saba, C., Ranchère, D., ... & Ray-Coquard, I. (2006). Sarcomas and malignant phyllodes tumours of the breast—a retrospective study. *European journal of cancer*, 42(16), 2715-2721.
6. Ramakant, P., Chakravarthy, S., Cherian, J. A., Abraham, D. T., & Paul, M. J. (2013). Challenges in management of phyllodes tumors of the breast: a retrospective analysis of 150 patients. *Indian Journal of Cancer*, 50(4), 345.
7. Confavreux, C., Lurkin, A., Mitton, N., Blondet, R., Saba, C., Ranchère, D., ... & Ray-Coquard, I. (2006). Sarcomas and malignant phyllodes tumours of the breast—a retrospective study. *European journal of cancer*, 42(16), 2715-2721.
8. Blanchard, D. K., Reynolds, C. A., Grant, C. S., & Donohue, J. H. (2003). Primary nonphylloides breast sarcomas. *The American journal of surgery*, 186(4), 359-361.
9. Taira, N., Takabatake, D., Aogi, K., Ohsumi, S., Takashima, S., Nishimura, R., & Teramoto, N. (2007). Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin. *Japanese journal of clinical oncology*, 37(10), 730-736.
10. Collin, F., Gelly-Marty, M., Binh, M. B. N., & Coindre, J. M. (2006). Sarcomes des tissus mous.
11. Salvadori, B., Cusumano, F., Bo, R. D., Delledonne, V., Grassi, M., Rovini, D., ... & Clemente, C. (1989). Surgical treatment of phyllodes tumors of the breast. *Cancer*, 63(12), 2532-2536.

12. Pandey, M., Mathew, A., Kattoor, J., Abraham, E. K., Mathew, B. S., Rajan, B., & Nair, K. M. (2001). Malignant phyllodes tumor. *The breast journal*, 7(6), 411-416.

13. Malard, Y., de Lara, C. T., MacGrogan, G., Bussières, E., Avril, A., Picot, V., ... & Coindre, J. M. (2004). Sarcomes primitifs du sein: À propos d’une série rétrospective de 42 cas traités à l’Institut Bergonié sur une période de 32 ans. *Journal de gynécologie obstétrique et biologie de la reproduction*, 33(7), 589-599.